Home News HCV Treatment Enters Transformative Era HCV Treatment Enters Transformative Era June 15, 2011 June 15, 2011 (Vol. 31, No. 12) Hepatitis C Virus Protease Inhibitor Agents Herals Major Advances in Field NewsAntiviral agentsCellular, Molecular and Developmental BiologyDiagnosisDNA typingDNA virusesDrugsForensic geneticsGeneticsHepatitis virusMedicine, Diagnosis, and TherapeuticsMicrobiologyMicroorganismsMolecular biologyPharmacologyPolymerase chain reactionPrognosisRNA biologySustained virologic responseTreatment outcomeViral RNAVirus Also of Interest Visual Proteomics: Observing Protein Location in Living Cells StockWatch: PacBio Faces Uphill Climb as Q1 Revenue Falls Short Gene Network Interactions Shed Insight into Breast Cancer Onset and Development Study Identifies 43 Potentially Causal Genes for PTSD Bruker to Acquire NanoString with $392.6M Winning Bid SPARDA: A Programmable Nucleic Acid Targeting Technology Like CRISPR Related Media Genetics in DC: A Report from ASHG BIO CEO Rachel King Outlines Industry's Challenges on "Close to the Edge" Carl Icahn States His Case for Change at Illumina on "Close to the Edge" Celebrating DNA: Matthew Cobb's Reflections on the Double Helix Emerging Markets Collaborate to Succeed in Post-Pandemic World Food For Thought: Final Report from the AGBT Ag Meeting Related Content Visual Proteomics: Observing Protein Location in Living Cells StockWatch: PacBio Faces Uphill Climb as Q1 Revenue Falls Short Gene Network Interactions Shed Insight into Breast Cancer Onset and Development Study Identifies 43 Potentially Causal Genes for PTSD